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A B S T R A C T
Fatty acid ethanolamides acting on proliferator-activated receptor (PPAR)-α are among the endogenous lipid
molecules that attenuate inflammatory processes and pain sensitivity. Whereas these properties are well-known
for palmitoylethanolamide (PEA), the efficacy of oleoylethanolamide (OEA, first described as a satiety hormone
synthesized in the jejunum) has been overlooked. In this study, we aimed to evaluate the effect of OEA ad-
ministration in a mouse model of colitis. C57BL/6J mice were exposed to 2.5% dextran sodium sulphate (DSS) in
drinking water for 5 days. Daily i.p. administration of 10 mg/kg OEA started 3 days before DSS and lasted for 12
days. The DSS-untreated control group received only ultrapure water. DSS mice treated with OEA had a sig-
nificant improvement of disease score. OEA restored mRNA transcription of PPAR-α, of tight junctions and
protective factors of colon integrity disrupted by DSS. The improvement correlated with significant decrease of
colonic and systemic levels of pro-inflammatory cytokines compared to the DSS group. OEA antiinflammatory
effects were mediated by the selective targeting of the TLR4 axis causing a downstream inhibition of nuclear
factor kappa B (NF-κB)- MyD88-dependent and NLRP3 inflammation pathways. OEA treatment also inhibited
DSS-induced increase of inflammatory cytokines levels in the mesenteric lymph nodes.
Conclusions and implications: These results underscore the validity of OEA as a potent protective and anti-in-
flammatory agent in ulcerative colitis that may be exploited to broaden the pharmacological strategies against
inflammatory bowel disease.
1. Introduction
Lipid mediators such as palmitoylethanomide (PEA) and oleoy-
lethanolamide (OEA) have emerged as prominent intrinsic regulators of
pain and inflammation [1,2]. Host-defence cells can generate these
bioactive lipids on demand and express their receptors. OEA exerts anti-
inflammatory effects on LPS-stimulated, immortalized monocytes
(THP-1) by activating the proliferator-activated receptor-alpha (PPAR-
α) and modulates maturation of dendritic cells via activation of the
transient receptor potential vanilloid 1 (TRPV1; [3]). In the intestinal
tract where it is synthesised, OEA plays a key role in gut physiology and
dysregulation of its metabolism is associated to intestinal diseases.
Nutrients containing oleic acid enhance the biosynthetic pathways of
OEA resulting in an overall increase in the lipid levels [4]. In an in-
flammatory condition such as colitis the intestinal proteins that trans-
port long-chain fatty acids like oleic acid are strongly reduced. An
immunohistochemical study showed that the expression of peroxisome
proliferator receptor (PPAR)-α (for which OEA has high affinity) is
decreased in biopsies of colonic epithelium from subjects with active
colitis, relative to healthy subjects [5]. This change is accompanied by a
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marked local decrease of the fatty amide ethanolamides (FAE) synthe-
sizing enzyme N-acyl phosphatidylethanolamine-specific phospholipase
D (NAPE-PLD) expression, and an increase of the degrading enzyme N-
acylethanolamine-hydrolyzing acid amidase (NAAA) expression [5].
We recently showed that OEA reduces intestinal cytokine expression by
immune cells isolated from Peyer’s patches, one of the immune sensors
of the intestine [6].
All these observations set up the rational for investigating the pro-
tective effect of OEA in a murine model of intestinal inflammatory
disease (IBD). A large and growing number of people worldwide is di-
agnosed with IBD, a debilitating pathology characterized by both acute
and chronic inflammation of the gastro-intestinal tract, with poorly
effective treatments. In our study, we used the dextran sodium sulphate
(DSS)-induced colitis. This animal model exhibits many characteristic
features of IBD in humans, including severe inflammation associated
with diarrhoea, weight loss, recruitment of immune cells and their
subsequent activation, altered macrophage function. Therefore, DSS-
induced colitis has been considered an indispensable tool to decipher
the underlying mechanisms of IBD pathogenesis, as well as to evaluate
potential therapeutics. Little is known though of the efficacy of OEA to
counteract inflammatory colitis. The only indication of a possible role
of OEA in intestinal homeostasis are the results of a clinical trial de-
scribing a significant increase of mast cells count and reduction of OEA
levels in colonic biopsies of patients affected by IBD, in comparison
with healthy subjects [7];(ClinicalTrial.gov NCT01370720); conversely
another report describes a modest increase of OEA in the plasma of IBD
patients [8].
In our study, we evaluated the effects of OEA administration in
C57BL/6J mice exposed to DSS for 5 days. It has been reported that this
mouse strain develops acute colitis that progresses to severe chronic
inflammation even with such a short term treatment [9]. The specific
purpose of our study was to investigate the systemic and intestinal
protective, immunomodulatory and anti-inflammatory effect of OEA,
by testing its ability to prevent gut barrier damage, to reduce in-
flammatory responses through TLR4/NLRP3 pathways, and in-
flammatory mesenteric lymph nodes microenvironment.
2. Materials and methods
2.1. Animals
All the experiments were approved by the Animal Care Committee
of the Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e
Salute del Bambino, Sezione di Farmacologia e Tossicologia, Universitá
di Firenze (I). Ethical policy of the Universitá di Firenze complies with
the Guide for the Care and Use of Laboratory Animals of the Council
Directive of the European Community (2010/63/EU) and the Italian
Decreto Legislativo 26 (13/03/2014). C57Bl/6, 8–10 weeks old male
mice (25−30 g) were used, bred and housed in macrolon cages in
temperature-controlled rooms (20–24 °C) in a dedicated room at Centre
for Laboratory Animals Università di Firenze (I). They were allowed
free access to food and water and kept on a 7:00−19:00 light/dark
cycle. Every effort was made to minimize animal suffering and to re-
duce the number of animals used. Animals were handled for at least 4
days before experiments begun, to let them get used to human contact
and then they were randomly assigned to the experimental groups.
2.2. Induction of colitis and treatment
Experimental colitis was induced by 2.5 % wt:vol dextran sodium
sulphate (DSS, 36–50 kDa, MP Biomedical) in drinking water available
ad libitum from day 3 (D3) after the beginning of experimental ob-
servations (D0) until D7, followed by DSS‐free water from D8 to D11
(end of experimental protocol). Mice were randomly divided into the
following groups: 1) control mice; 2) mice receiving DSS and vehicle; 3)
mice receiving DSS and OEA. OEA (Tocris Bioscience, UK) was
dissolved in saline/polyethylene glycol/Tween80 (90/5/5, v/v) and
administered i.p. at a dose of 10 mg/kg from D0 to D11 as a preventive
therapy. The dose of OEA was within the range of i.p. doses previously
reported in the literature [6,10–13]. Animals were sacrificed by cervical
dislocation and sample collected immediately after.
2.3. Evaluation of experimental colitis
Mice were weighted and food consumption measured daily from D0
to D11. Presence of blood and stool consistency were determined daily
as previously described [14]. Scores were determined as follows: a)
weight change (0: weight loss< 1 % compared with starting weight; 1:
weight loss between 1 and 5 %; 2: weight loss between 6 and 15 %; 4:
weight loss> 15 %); b) blood in stool: 0, no visible blood; 2, blood
visible in stools; 4, frank bleeding from the anus and/or fresh or dried
blood around the anus; c) stool consistency: 0, normal; 2, pasty and
semi-formed stools that do not adhere to the anus; 4, liquid stools (may
adhere to the anus). The disease activity index (DAI) was determined by
adding the scores obtained in the 3 above-mentioned parameters and by
dividing the sum by 3. At day 12 mice were sacrificed, tissues were
collected and colon length measured.
2.4. Serum parameters
Blood was collected by cardiac puncture. Sera were obtained by
centrifugation at 1500 × g at 4 °C for 15 min and stored at−70 °C until
use. Serum interleukin (IL)-1, IL-6, IL-10, (Thermo Scientific, Rockford,
IL, USA), tumour necrosis factor-α (TNF-α) (Biovendor R&D, Brno,
Czech Republic) were determined using commercially available ELISA
kits. Lipopolysaccharide (LPS) was measured using the Limulus ame-
bocyte lysate (LAL QCL-1000; Lonza Group Ltd., Basel, Switzerland)
technique.
2.5. Real-Time semi-quantitative PCR
Total RNA, isolated from colon, was extracted following protocols as
previously reported (Lama et al. 2019). Each cDNA sample (500 ng)
was mixed with 2X QuantiTech SYBRGreen PCR Master Mix and pri-
mers, Tnfa, Nlrp3, Il1b, Il6, Myd88, Ocln, Tijp1, Muc2, Pparα (Qiagen,
Hilden, Germany). The relative amount of each studied mRNA was
normalized to Actb as a housekeeping gene, and the data were analysed
according to the 2−ΔΔCt method. Real-Time PCR was performed by
CFX96 instrument (Bio-Rad, Segrate, Italy).
2.6. Western blotting
After homogenization, the colon was lysed and total protein lysates
underwent SDS-PAGE as described [14]. Filters were probed with
polyclonal antibody against anti-NFκB (Cell Signaling Technology,
Danvers, MA, USA), anti-TLR4 and anti-IκBα (Santa Cruz Bio-
technology, Dallas, TE, USA). To evaluate NF-κB activation, NF-κB p65
and IκBα were measured in nuclear and cytosolic extracts, respectively,
as previously described [15]. Western blot analysis for β-Actin (Sigma-
Aldrich, Milan, Italy) was performed to ensure equal sample loading.
Bands were detected by ChemiDoc imaging instrument (Bio-Rad, Seg-
rate, Italy).
2.7. Mesenteric lymph nodes isolation and cytokines determination
Mice were sacrificed by cervical dislocation without anaesthesia.
Mesenteric lymph nodes were isolated from mice intestine and trans-
ferred in a 15 ml tube with PBS + 1% Pen/Strep (Lonza, Germany).
Mesenteric lymph nodes were next mechanically dissociated on a 70 μm
cell strainer (Falcon, USA) placed over 50 ml tube. During dissociation,
filters were washed with RPMI + 1 % Pen/Strep. Cells flowed through
the filter and were suspended in 15 ml of RPMI, 10 % FBS, 1% Pen/
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Strep, 0,01 % β-mercaptoethanol, 1 % L-glutamine, 1 % Na-Pyr and 1 %
Hepes (complete medium). Cells were next centrifuged for 10 min at
1300 rpm and at room temperature. The supernatants were discarded
and pellets were re-suspended in complete medium. Mesenteric lymph
nodes cells were counted with Thomas chamber using Trypan blue dye
to exclude dead cells. Mesenteric lymph nodes experiments were done
in triplicate to ensure reliability of single values. Cells were then plated
at the concentration of 1 × 105 cells/100 μl (1 × 106 cells/mL) in 96-
well plate in the presence of PHA (5 ug/mL), (Sigma-Aldrich, USA) or
vehicle for 48 h, in a 37 °C and 5% CO2 incubator. After incubation cell
supernatants were collected to determine the following soluble factors:
IFNγ, IL-4, IL-6, I-L10, IL-17, TNF-α, CXCL2, by Luminex Technologies
(Procartaplex, Life Technologies, USA).
2.8. Data and statistical analysis
Sample size was determined by power analysis based on effect sizes
previously reported for similar compounds and protocols [14] by using
Gpower software. Measurements and data analysis were performed by
operators not aware of the experimental groups the samples belonged
to. In some circumstances, normalization was employed to control for
unwanted sources of variability. Experiments were done in triplicate to
ensure reliability of single values. Statistical analysis was performed by
one-ANOVA followed by Bonferroni’s post-hoc test for multiple com-
parisons. Differences among groups were considered significant at va-
lues of p<0.05. Analyses were performed using GraphPad Prism 7
(GraphPad Software, San Diego, CA, USA). The data and statistical
analysis comply with the recommendations on experimental design and
analysis in pharmacology [16].
3. Results
3.1. OEA treatment reduced DSS-induced colon tissue damage and disease
activity index
The treatment with OEA significantly attenuated the development
of colitis evaluated as DAI during the 11 days of the protocol when
compared to mice receiving DSS and vehicle (Fig. 1A). Body weight and
food consumption were also monitored throughout the experimental
period (Fig. 1B, C). Despite of food consumption being not significantly
different among experimental groups, DSS-treated mice lost weight
with respect to controls and OEA did not prevent this effect. This is not
unexpected, given the hypophagic properties of OEA [13]. Diarrhoea
was present in DSS + Veh treated mice and OEA ameliorated sig-
nificantly this parameter, as values were not significantly different from
controls up to day 9 (Fig. 1D). DSS-induced bleeding was also sig-
nificantly reduced by OEA treatment (Fig. 1E). The beneficial effects of
OEA were also evident in the excised colon samples, as it partially
prevented DSS-induced colon shortening (Fig. 1F).
3.2. OEA counteracted systemic and local inflammation induced by DSS
The DSS challenge triggered a strong systemic inflammation in-
duced by the pathogen-associated molecular pattern (PAMP), LPS
(Fig. 2A). Plasma LPS levels were evaluated as an indirect measurement
of gut permeability to endotoxin. As shown in Fig. 2A, OEA pre-treat-
ment partially prevented DSS effect. The detrimental effect of DSS was
also displayed by increased serum levels of the pro-inflammatory cy-
tokines TNF-α, IL-1β, IL-6 (Fig. 2B–D) and the reduced levels of anti-
inflammatory IL-10 (Fig. 2E) compared to controls. OEA treatment
partially (Fig. 2C–E) or completely (Fig. 2D) prevented the onset of the
systemic inflammation. The beneficial effects induced by OEA admin-
istration on systemic inflammation mirrored a strong improvement of
colon tissue damage. As shown in Fig. 3, DSS treatment increased sig-
nificantly mRNA expression of the pro-inflammatory cytokines TNF-α,
IL-1β and IL-6 in the colon mucosa. OEA abolished DSS-induced in-
testinal inflammatory profile, as there were no significant differences
between DSS-OEA treated mice and controls.
3.3. OEA limited DSS-induced inflammatory immune cell recruitment
We also determined the effect of OEA on the TLR4/NF-κB complex
in the colon mucosa, as this classical pathway controls the induction of
pro-inflammatory cytokines and chemokines. DSS-challenged mice
showed a significantly increased expression of TLR4 protein, the main
LPS receptor in the gut (Fig. 4A). Furthermore, DSS induced the nuclear
translocation of the p65 subunit of NF-κB (Fig. 4B) and decreased the
cytosolic expression of IκBα, the inhibitory protein of NF-κB (Fig. 4C).
These effects were completely prevented by OEA treatment, as there
were no significant differences between DSS-OEA treated mice and
Fig. 1. Effects of OEA on DSS-induced tissue damage and body weight change. (A) Disease activity index (DAI) during the 11 days of experimental protocol. (B) Time
course of changes in body weight and (C) cumulative food consumption. (D) Time course of stool consistency and (E) Blood in stool indexes. (F) Colon length
expressed in cm; samples were excised at day 11. *p<0.05, **p<0.01, ***p<0.001, vs control; ### p<0.001 vs DSS. Comparison among groups were made by
one-way analysis of variance followed by Bonferroni’s post hoc test. N = 13-19 in panels A, B, C, D, E; N = 10-15 in panel F).
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controls. As shown in Fig. 4D, the DSS-induced pro-inflammatory pro-
file involved the Myeloid differentiation primary response (Myd)88b-
dependent signalling pathway, that mediates the early-phase activation
of NF-κB. Furthermore, DSS altered gut immune response inducing
mRNA expression of NACHT, LRR and PYD domains-containing protein
3 (NLRP3; Fig. 4E). The beneficial effects of OEA were reflected on all
gut immune response to PAMPs tested, as well as on the transcription of
the inflammasome, as there were no significant differences between
DSS-OEA treated mice and controls.
3.4. OEA modulated immune cytokines and chemokines in mesenteric
lymph nodes
In order to study the immune adaptive response, we evaluated cy-
tokine production by T lymphocytes isolated from mesenteric lymph
nodes, after stimulation with the mitogen phytohaemagglutinin (PHA).
As shown in Fig. 5, DSS significantly increased the production of the
pro-inflammatory cytokines IFN-γ, IL-6, IL-17, TNF-α, IL-4 and of the
regulatory cytokine IL-10 compared to control mice. Neutrophil recall
chemokine CXCL2 was also significantly increased by DSS treatment.
The administration of OEA prevented the DSS effect on IFN-γ, IL-6 IL-
17, CXCL2 as results were not different from controls. OEA decreased
TNF-α, IL-4, IL-10 significantly with respect to both DSS + VEH and
Controls.
3.5. Effects of OEA on intestinal barrier integrity
The local and systemic pro-inflammatory profile induced by DSS
entails a disruption of the intestinal barrier. Tight junction status is a
good marker for barrier integrity loss. Therefore, we investigated the
expression of two main tight junction proteins in the distal colon, oc-
cludin (Ocln) and tight junction protein-1 (Tijp1) which are involved in
preserving the gut integrity [17]. The administration of DSS induced a
significant reduction of these tight junction proteins, and their levels
were restored by OEA treatment (Fig. 6A, B). Moreover, OEA prevented
DSS-induced reduction of mucin 2 (Muc2) which is involved in mucus
production and triggered the transcription of Trefoil factor 3 (Tff3) an
essential protein in gut protection (Fig. 6C, D). In addition, we mea-
sured PPAR-alpha expression in the various experimental conditions to
investigate if this receptor confers protection against intestinal injury
[18]. As shown in Fig. 6E, DSS treatment significantly decreased PPAR-
α mRNA expression, and OEA completely prevented this effect.
Fig. 2. Effects of OEA on DSS-induced systemic inflammation. DSS significantly increased serum levels of LPS (A), TNF-α(B), IL-1β(C), IL-6(D), and decreased the
levels of anti-inflammatory IL-10 (E). OEA treatment limited all these effects. Results are shown as mean± SEM (n = 5). ***p<0.001, ****p<0.0001, vs controls;
#p<0.05, ##p<0.01, #### p<0.0001 vs DSS. Comparison among groups were made by one-way analysis of variance followed by Bonferroni’s post hoc test.
Fig. 3. OEA reduced DSS-induced colon inflammation. DSS significantly increased colon mucosa transcription levels of TNF-α (A), IL-1β (B) and IL-6 (C). OEA
treatment prevented these effects. Results are shown as mean± SEM (n = 5). ****p<0.0001, vs controls; ####p<0.0001 vs DSS. Comparison among groups
were made by one-way analysis of variance followed by Bonferroni’s post hoc test.
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4. Discussion
Current treatments of intestinal inflammatory diseases have short-
term efficacy and induce severe side effects; thus, the search for new
therapeutic targets is relentless and represents a challenge for physi-
cians and pharmacologists. Crohn’s disease and ulcerative colitis are the
major forms of IBD characterized by bowel inflammation and abdom-
inal pain. Over the last decade the development of animal models of
intestinal inflammation, such as DSS-induced colitis, has facilitated
significant advances in our understanding of human pathologies. In our
study, we found that OEA has a potent protective effect against all
macroscopic and pathological changes of DSS colitis. The main findings
of our study are the following: DSS-induced ulcerative colitis produces
local gut inflammation and alteration of colonic tight junctions complex
that presumably allows the contact of bacteria with mesenteric lymph
nodes, the passage of LPS to the bloodstream and systemic
Fig. 4. Effects of OEA on gut immune response altered by DSS. DSS significantly increased TLR4 (A), increased the nuclear level of NF-κB p50 subnunit (B), whereas it
decreased cytosolic expression of IκBα (C). Cropped Western blots are shown for each parameter. Furthermore, DSS augmented the transcription of Myd88 (D) and
the inflammasome NLRP3 (E). OEA limited the protein levels and mRNA expression of all parameters. Results are shown as mean± SEM (for Western blot, n = 4 and
for Real Time PCR, n = 6). *p<0.05, **p<0.01, ****p<0.0001, vs control; #p<0.05, ##p<0.01, #### p<0.0001 vs DSS. Comparison among groups were
made by one-way analysis of variance followed by Bonferroni’s post hoc test.
Fig. 5. OEA prevented DSS-induced changes of cytokines and chemokines secretion in intestinal mesenchymal lymph nodes. Protein production was determined by
Luminex technology on cells supernatants. Cells were activated by PHA (5 μg/mL). DSS treatment increased the release of pro-inflammatory cytokines IFN-γ, IL-6, IL-
17, TNF-α, IL-4 and the chemokine CXCL2, and the regulatory cytokine IL-10. OEA completely abolished the mesenteric lymph nodes inflammatory profile. Each
histogram represents mean value± SEM of protein concentration (pg/mL) of 3 samples for each group from 6 independent experiments. **p<0.01; ***p< 0.001;
****p<0.0001, vs control; ##p<0.01; #### p<0.0001 vs DSS. Comparison among groups were made by one-way analysis of variance followed by Bonferroni’s
post hoc test.
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inflammation; OEA pre-treatment significantly reduced system in-
flammation; prevented colonic inflammation, the production of pro-
inflammatory cytokine in mesenteric lymph nodes, and preserved the
alterations of gut integrity induced by DSS.
The mucosal barrier disruption may indeed be one of the first events
to trigger subsequent cascade of processes that evolve in DSS-induced
colonic, lymphatic and systemic inflammatory response.
Our results strongly suggest that OEA may prevent the disruption of
the mucosal barrier, as it normalized mRNA expression of the tight
junction proteins occludin and zonuline-1, and promoted the expression
of protective factors such as mucin and Tff3. These data are in agree-
ment with the observation that the inflamed tissues of patients with IBD
[19] and of DSS animals [14] showed impairment of tight junction
proteins and local inflammation, also determined by the increase of
IFN-γ. IFN-γ plays a pivotal role on barrier permeability impairment in
IBD, triggering the internalization of TJ proteins [20]. The strong re-
duction of IFN-γ in intestinal mesenchymal lymph nodes supports the
positive effect of OEA on the recovery of intestinal integrity.
In pathological conditions, tight junctions are disrupted exposing
TLR4 localized mainly in the basolateral surfaces of the enterocytes of
the small intestine to pathogens, triggering the inflammatory response.
In turn, inflammation may exacerbate barrier dysfunction, as TLR4
activation and the pro-inflammatory cytokine TNF-α modulate colonic
tight junction permeability [21]. In this regard, TLR4 expression is
upregulated in patients with IBD [22], in particular Crohn’s disease and
ulcerative colitis [23,24]. We found that OEA completely prevented
DSS-induced activation of the TLR4 cascade in the colon hence reduced
colon inflammation, by restoring the levels of MyD88, the cytosolic
adaptor protein that transfers signals between TLR4 and NFK-bB, NF-kB
and IKK.
In our experimental condition, OEA prevented the activation of the
inflammasome NLRP3, maintaining the levels of inflammatory cyto-
kines within the controls’ range. In this regard, it was reported that in
NLRP3 knockout mice oral administration of DSS produced a less severe
colitis than in wild-type mice and lower levels of pro-inflammatory
cytokines in the colon tissue [25].
In our model, ulcerative colitis is associated with increased serum
levels of TNF-α, IL-1β, IL-6 that are considered as peripheral markers of
inflammation. The anti-inflammatory profile afforded by OEA pre-
treatment was also extended to systemic actions in the bloodstream, as
we observed reduced levels of serum LPS and pro-inflammatory cyto-
kines, mirroring colonic anti-inflammatory effects. The study of in-
flammation and functional profile of mesenteric lymph node T cells
may provide information on ulcerative colitis pathogenesis.
Surveillance against pathogens is performed by both innate and the
adaptive immune systems. Mucosal Th cells regulate gut homeostasis
and along with dendritic cells and macrophages have a prominent role
both in the acute and chronic phases of colitis [26]. In DSS mice, OEA
blunted the mesenteric lymph nodes immune adaptive response redu-
cing cytokine and chemokine levels. Although we did not check me-
senteric lymph node T cells phenotype, the absence of IL-10 production
in DSS + OEA treated animals suggests that CD4+CD25+FoxP3+ T
cells (Treg) are not increased and that the anti-inflammatory effect
might be mainly mediated by antigen presenting cells as dendritic cells.
These results are in agreement with our previous observation that OEA
polarises gut-specific immune responses towards an anti-inflammatory
profile in healthy mice [6].
Previous data reported that OEA treatment induced a similar anti-
inflammatory and protective effect of the gut barrier in alcohol binging
rats [27], although in these animals OEA administration did not reduce
plasma LPS nor prevented bacterial translocation to the mesenteric
lymph nodes.
In our model, OEA’s mechanisms of action are presumably multi-
farious. OEA binds with high affinity to PPAR-α, which is abundantly
expressed in enterocytes. In our study, OEA completely restored mRNA
expression of PPAR-α in the colon mucosa, which is presumably re-
sponsible for the overall protective effect of OEA on DSS-induced da-
mages. These results are in accord with previous observations demon-
strating that activation of PPAR-α protects the intestinal mucosa from
injuries of various nature [18,28].
PPARs including PPAR-α, are involved in the response to treatment
in patients with ulcerative colitis and PPAR-α low gene expression in
human mucosa confers a higher risk of ulcerative colitis [29]. It is well
known that PPAR-α plays a role in controlling mucosal tissue
Fig. 6. OEA improved gut integrity of DSS mice. DSS decreased mRNA expression of two main tight junctions, occluding (A) and zonulin-1 (TIJP1; B), and increased
mRNA levels of mucin (Muc (C) and Tff3 (D). DSS also decreased the expression of PPAR-α (E). OEA prevented all DSS induced changes. Results are shown as
mean± SEM (n = 5). **p<0.01, ***p<0.001, vs CON; #p<0.05, ##p<0.01, vs DSS. Comparison among groups were made by one-way analysis of variance
followed by Bonferroni’s post hoc test.
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homeostasis and PPAR-α agonists improve DNBS- and DSS-induced
colitis [30–32]. However, we cannot exclude other mechanisms of ac-
tion. For instance, some of the homeostatic effects of OEA are mediated
by the activation of TRPV1. In Caco-2 cell monolayer used to assess
permeability, OEA increased the transepithelial resistance when ap-
plied to the apical membrane and capsazepine, a TRPV1 antagonist,
blocked this effect [33]. Moreover, OEA downregulates TLR4/NF-κB
pathway leading to dendritic cells maturation through the activation of
TRPV1 [34]. Activation of these receptors may contribute to the anti-
inflammatory properties of OEA in DSS induced colitis. OEA is also a
medium-potency agonist for GPR119 [35], but presumably this re-
ceptor is not directly involved in intestinal barrier maintenance nor
inflammatory responses (reviewed in [36]). However, the activation of
GPR119 mediates the release of GLP-1, a peptide that increases in DSS
colitis [37] and is endowed with anti-inflammatory properties [38].
Recently, analysis of faecal biodiversity showed that OEA treatment
modifies the intestinal microbial composition of healthy mice [18]. As
changes in the microbiota are associated with intestinal [39], im-
munological and metabolic diseases [40], OEA may as well afford a
protective action in the intestine by mitigating the dysbiosis that fol-
lows not only DSS treatment in animals, but also IBD in humans [41].
Beyond its preventive anti-inflammatory effects showed by our data,
it is well-known that food intake promotes OEA formation in the small
intestine, in particular nutrients containing oleic acid enhance the
biosynthetic pathways of OEA resulting in an overall increase in the
lipid levels [42]. A recent study reported that extra-virgin olive oil, that
contains high levels of oleic acid, the precursor of OEA, and phenols,
displays a protective effect in liver dysfunction and gut inflammation in
DSS-induced colitis in mice [43]. Therefore, stimulating endogenous
OEA synthesis with dietary intervention or supplementing OEA itself
may contribute to the successful treatment of inflammatory-based in-
testinal diseases.
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